Accuracy of an off-label transmitter and data manager paired with an intermittent scanned continuous glucose monitor in adults with type 1 diabetes / Carlos Esteban Builes Montaño  

Público ISBD Título : Accuracy of an off-label transmitter and data manager paired with an intermittent scanned continuous glucose monitor in adults with type 1 diabetes Tipo de documento : documento electrónico Autores : Carlos Esteban Builes Montaño, Autor Fecha de publicación : 2022 Títulos uniformes : Journal of Diabetes Science and Technology Idioma : Inglés (eng) Palabras clave : FreeStyle Libre  MiaoMiao transmitter  continuous glucose monitoring  intermittent scanned glucose monitoring  xDrip+ software Resumen : Background: This work evaluates the accuracy and agreement between the FreeStyle Libre sensor (FSL) and an off-label converted real-time continuous glucose monitor (c-rtCGM) device consisting of the MiaoMiao transmitter and the xDrip+ application which can be coupled to the FSL. Methods: Four weeks of glucose data were collected from 21 participants with type 1 diabetes using the c-rtCGM and FSL: two weeks with a single initial calibration (uncalibrated) and two weeks with a daily calibration (calibrated). Accuracy and agreement evaluation included mean absolute relative difference (MARD), the %20/20 rule, Bland-Altman plots, and the Consensus Error Grid analysis. Results: Values reported by the c-rtCGM system compared with the FSL resulted in an overall MARD of 12.06% and 84.71% of the results falling within Consensus Error Grid Zone A when the device is calibrated. For uncalibrated devices, an overall MARD of 17.49% was obtained. Decreased accuracy was shown in the hypoglycemic range and for rates of change greater than 2 mg/dL/min. The between-device bias also incremented with increasing glucose values. Conclusion: Measurements recorded by the c-rtCGM were found to be accurate when compared with FSL data only when performing daily c-rtCGM device calibrations. High drops in accuracy and agreement between devices occurred when the c-rtCGM was not calibrated. Mención de responsabilidad : María F Villa-Tamayo, Carlos E Builes-Montaño, Alex Ramirez-Rincón, Javier Carvajal Pablo S Rivadeneira Referencia : J Diabetes Sci Technol. 2022 Oct 25;19322968221133405. DOI (Digital Object Identifier) : 10.1177/19322968221133405 PMID : 36281579 En línea : https://journals.sagepub.com/doi/10.1177/19322968221133405 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6073 Accuracy of an off-label transmitter and data manager paired with an intermittent scanned continuous glucose monitor in adults with type 1 diabetes [documento electrónico] / Carlos Esteban Builes Montaño, Autor . - 2022. Obra : Journal of Diabetes Science and Technology Idioma : Inglés (eng) Palabras clave : FreeStyle Libre  MiaoMiao transmitter  continuous glucose monitoring  intermittent scanned glucose monitoring  xDrip+ software Resumen : Background: This work evaluates the accuracy and agreement between the FreeStyle Libre sensor (FSL) and an off-label converted real-time continuous glucose monitor (c-rtCGM) device consisting of the MiaoMiao transmitter and the xDrip+ application which can be coupled to the FSL. Methods: Four weeks of glucose data were collected from 21 participants with type 1 diabetes using the c-rtCGM and FSL: two weeks with a single initial calibration (uncalibrated) and two weeks with a daily calibration (calibrated). Accuracy and agreement evaluation included mean absolute relative difference (MARD), the %20/20 rule, Bland-Altman plots, and the Consensus Error Grid analysis. Results: Values reported by the c-rtCGM system compared with the FSL resulted in an overall MARD of 12.06% and 84.71% of the results falling within Consensus Error Grid Zone A when the device is calibrated. For uncalibrated devices, an overall MARD of 17.49% was obtained. Decreased accuracy was shown in the hypoglycemic range and for rates of change greater than 2 mg/dL/min. The between-device bias also incremented with increasing glucose values. Conclusion: Measurements recorded by the c-rtCGM were found to be accurate when compared with FSL data only when performing daily c-rtCGM device calibrations. High drops in accuracy and agreement between devices occurred when the c-rtCGM was not calibrated. Mención de responsabilidad : María F Villa-Tamayo, Carlos E Builes-Montaño, Alex Ramirez-Rincón, Javier Carvajal Pablo S Rivadeneira Referencia : J Diabetes Sci Technol. 2022 Oct 25;19322968221133405. DOI (Digital Object Identifier) : 10.1177/19322968221133405 PMID : 36281579 En línea : https://journals.sagepub.com/doi/10.1177/19322968221133405 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6073

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001917	DD001917	Archivo digital	Producción Científica	Artículos científicos	Disponible

Efficacy and safety of carbohydrate counting versus other forms of dietary advice in patients with type 1 diabetes mellitus: a systematic review and meta-analysis of randomised clinical trials / Carlos Esteban Builes Montaño ; Natalia Andrea Ortíz Cano ; Natalia Andrea Rojas Henao  

Público ISBD Título : Efficacy and safety of carbohydrate counting versus other forms of dietary advice in patients with type 1 diabetes mellitus: a systematic review and meta-analysis of randomised clinical trials Tipo de documento : documento electrónico Autores : Carlos Esteban Builes Montaño, ; Natalia Andrea Ortíz Cano, ; Natalia Andrea Rojas Henao, Fecha de publicación : 2022 Títulos uniformes : Journal of Human Nutrition and Dietetics Idioma : Inglés (eng) Palabras clave : carbohydrate counting  diabetes mellitus  diet therapy  dietary carbohydrates  glycated haemoglobin A Resumen : Background and aims: Diabetes mellitus (DM) is one of the most prevalent chronic noncommunicable diseases globally, and the only way to reduce its complications is good glycaemic control. Insulin remains the only approved treatment for type 1 DM (T1DM) and is used by many with type 2 DM (T2DM). Carbohydrate counting is considered the ideal way to calculate meal-related insulin doses as it allows greater flexibility in diet and could, in some people, reduce the burden of the disease. The primary objective of this systematic review was to assess carbohydrate counting efficacy in reducing glycated haemoglobin (HbA1c) levels and safety by not increasing hypoglycaemia risk, inducing an increase in body weight or blood lipids, or reducing the quality of life of people with T1DM. Methods: We included randomised controlled clinical trials with a parallel-group design comparing any carbohydrate counting forms with standard care or other forms of dietary advice or insulin dose calculation in people with T1DM with a follow up period of at least 3 months and with no restrictions in language, age or settings. As a primary outcome, we consider the change of HbA1c levels within at least 3 months. Secondary outcomes were hypoglycaemia events, body weight changes, blood lipids levels, and the total daily insulin dose. We also evaluated health-related quality-of-life changes and questionnaires on satisfaction with treatment of diabetes. Results: Data from 11 studies with 899 patients were retrieved with a mean follow-up of 52 ± 35.5 weeks. Carbohydrate counting is not better in reducing HbA1clevels (SMD-0.24%, 95% CI −0.68 to 0.21) than all dietary advice forms. However, this finding was highly heterogeneous. We identified three studies that account for most of the heterogeneity using clustering algorithms. A second analysis excluding these studies shows a meaningful reduction in HbA1c levels (SMD-0.52%, 95% CI −0.82 to −0.23) with low heterogeneity. In the subgroup analysis, carbohydrate counting significantly reduces HbA1c levels compared with usual diabetes education. Carbohydrate counting does not relate to any substantial change in blood lipids, body weight, hypoglycaemia risk or daily insulin dose. Finally, we analysed the effect of trial duration on reduction in HbA1c levels and found no significant change related to time. Conclusions: Carbohydrate counting is an efficacious technique to safely reduce the levels of HbA1c in adults and children compared with standard diabetes education, and its effect does not appear to change with prolonged time. Standardisation in reporting important outcomes such as hypoglycaemia and quality of life are vital to produce comparable evidence in carbohydrate counting clinical trials. This systematic review was registered in PROSPERO under code: CRD42020218499. Mención de responsabilidad : Carlos E. Builes-Montaño, Natalia A. Ortiz-Cano, Alex Ramirez-Rincón, Natalia A. Rojas-Henao Referencia : J Hum Nutr Diet. 2022 Dec;35(6):1030-1042. DOI (Digital Object Identifier) : 10.1111/jhn.13017 PMID : 35436364 En línea : https://onlinelibrary.wiley.com/doi/10.1111/jhn.13017 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6026 Efficacy and safety of carbohydrate counting versus other forms of dietary advice in patients with type 1 diabetes mellitus: a systematic review and meta-analysis of randomised clinical trials [documento electrónico] / Carlos Esteban Builes Montaño, ; Natalia Andrea Ortíz Cano, ; Natalia Andrea Rojas Henao,  . - 2022. Obra : Journal of Human Nutrition and Dietetics Idioma : Inglés (eng) Palabras clave : carbohydrate counting  diabetes mellitus  diet therapy  dietary carbohydrates  glycated haemoglobin A Resumen : Background and aims: Diabetes mellitus (DM) is one of the most prevalent chronic noncommunicable diseases globally, and the only way to reduce its complications is good glycaemic control. Insulin remains the only approved treatment for type 1 DM (T1DM) and is used by many with type 2 DM (T2DM). Carbohydrate counting is considered the ideal way to calculate meal-related insulin doses as it allows greater flexibility in diet and could, in some people, reduce the burden of the disease. The primary objective of this systematic review was to assess carbohydrate counting efficacy in reducing glycated haemoglobin (HbA1c) levels and safety by not increasing hypoglycaemia risk, inducing an increase in body weight or blood lipids, or reducing the quality of life of people with T1DM. Methods: We included randomised controlled clinical trials with a parallel-group design comparing any carbohydrate counting forms with standard care or other forms of dietary advice or insulin dose calculation in people with T1DM with a follow up period of at least 3 months and with no restrictions in language, age or settings. As a primary outcome, we consider the change of HbA1c levels within at least 3 months. Secondary outcomes were hypoglycaemia events, body weight changes, blood lipids levels, and the total daily insulin dose. We also evaluated health-related quality-of-life changes and questionnaires on satisfaction with treatment of diabetes. Results: Data from 11 studies with 899 patients were retrieved with a mean follow-up of 52 ± 35.5 weeks. Carbohydrate counting is not better in reducing HbA1clevels (SMD-0.24%, 95% CI −0.68 to 0.21) than all dietary advice forms. However, this finding was highly heterogeneous. We identified three studies that account for most of the heterogeneity using clustering algorithms. A second analysis excluding these studies shows a meaningful reduction in HbA1c levels (SMD-0.52%, 95% CI −0.82 to −0.23) with low heterogeneity. In the subgroup analysis, carbohydrate counting significantly reduces HbA1c levels compared with usual diabetes education. Carbohydrate counting does not relate to any substantial change in blood lipids, body weight, hypoglycaemia risk or daily insulin dose. Finally, we analysed the effect of trial duration on reduction in HbA1c levels and found no significant change related to time. Conclusions: Carbohydrate counting is an efficacious technique to safely reduce the levels of HbA1c in adults and children compared with standard diabetes education, and its effect does not appear to change with prolonged time. Standardisation in reporting important outcomes such as hypoglycaemia and quality of life are vital to produce comparable evidence in carbohydrate counting clinical trials. This systematic review was registered in PROSPERO under code: CRD42020218499. Mención de responsabilidad : Carlos E. Builes-Montaño, Natalia A. Ortiz-Cano, Alex Ramirez-Rincón, Natalia A. Rojas-Henao Referencia : J Hum Nutr Diet. 2022 Dec;35(6):1030-1042. DOI (Digital Object Identifier) : 10.1111/jhn.13017 PMID : 35436364 En línea : https://onlinelibrary.wiley.com/doi/10.1111/jhn.13017 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6026

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001867	AC-2022-032	Archivo digital	Producción Científica	Artículos científicos	Disponible

Hiperplasia adrenal congénita asociada a mutación no descrita en el gen CYP17A1 / Carlos Esteban Builes Montaño    

Público ISBD Título : Hiperplasia adrenal congénita asociada a mutación no descrita en el gen CYP17A1 Otros títulos : Congenital adrenal hyperplasia associated with a no described mutation in the CYP17A1 gene Tipo de documento : documento electrónico Autores : Carlos Esteban Builes Montaño, Fecha de publicación : 2022 Títulos uniformes : Revista Colombiana de Endocrinología Diabetes y Metabolismo Idioma : Español (spa) Palabras clave : hiperplasia suprarrenal congénita  esteroide 17-alfa-hidroxilasa  virilismo  hipertensión  desarrollo sexual  mutación Resumen : Introducción: la deficiencia de 17α-hidroxilasa/17,20-liasa es causada por un defecto en el gen CYP17A1 que codifica una enzima que expresa tanto actividad 17α-hidroxilasa como 17,20-liasa en las glándulas suprarrenales y las gónadas. El fenotipo de esta condición es muy característico, pero lo pueden compartir otros defectos enzimáticos y la adecuada relación genotipo-fenotipo es importante para el diagnóstico correcto, por lo que se recomienda enfocar el tratamiento y la consejería a los pacientes. Objetivo: reportar por primera vez una variante genética potencialmente relacionada con una hiperplasia adrenal congénita en una paciente con un fenotipo compatible con una deficiencia de 17α-hidroxilasa y 17,20-liasa. Presentación del caso: se presenta el caso de una mujer que consultó por infantilismo sexual y amenorrea primaria en presencia de cariotipo 46XX. Durante su evolución, cursó con hipertensión e hipokalemia que condujo a la sospecha diagnóstica de una hiperplasia adrenal congénita (HAC). El estudio genético reveló una mutación de cambio de sentido erróneo, homocigota, en el exón 8, c.1250T>C; p.Phe417Ser del gen de la CYP17A1. Se ha demostrado previamente que mutaciones en esta localización suprimen las actividades de 17α-hidroxilasa y 17,20-liasa, lo que explica el fenotípico clínico observado. Reportamos por primera vez en el mundo la mutación de cambio de sentido erróneo, c.1250T>C; p.Phe417Ser, en el gen CYP17A1, relacionada con la HAC. Discusión y conclusión: los análisis genéticos en todos los pacientes con HAC son necesarios para definir la frecuencia de esta y otras mutaciones en la población colombiana y relacionar el fenotipo de la enfermedad con su genotipo. Mención de responsabilidad : Carlos E. Builes-Montaño, Myriam V. Rueda-Galvis, María C. Fragozo-Ramos, Valentina Agredo-Delgado, Julián Zea-Lopera, Carlos M. Muñetón-Peña DOI (Digital Object Identifier) : 10.53853/encr.9.2.750 Derechos de uso : CC BY-NC-ND En línea : https://revistaendocrino.org/index.php/rcedm/article/view/750 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6060 Hiperplasia adrenal congénita asociada a mutación no descrita en el gen CYP17A1 = Congenital adrenal hyperplasia associated with a no described mutation in the CYP17A1 gene [documento electrónico] / Carlos Esteban Builes Montaño,  . - 2022. Obra : Revista Colombiana de Endocrinología Diabetes y Metabolismo Idioma : Español (spa) Palabras clave : hiperplasia suprarrenal congénita  esteroide 17-alfa-hidroxilasa  virilismo  hipertensión  desarrollo sexual  mutación Resumen : Introducción: la deficiencia de 17α-hidroxilasa/17,20-liasa es causada por un defecto en el gen CYP17A1 que codifica una enzima que expresa tanto actividad 17α-hidroxilasa como 17,20-liasa en las glándulas suprarrenales y las gónadas. El fenotipo de esta condición es muy característico, pero lo pueden compartir otros defectos enzimáticos y la adecuada relación genotipo-fenotipo es importante para el diagnóstico correcto, por lo que se recomienda enfocar el tratamiento y la consejería a los pacientes. Objetivo: reportar por primera vez una variante genética potencialmente relacionada con una hiperplasia adrenal congénita en una paciente con un fenotipo compatible con una deficiencia de 17α-hidroxilasa y 17,20-liasa. Presentación del caso: se presenta el caso de una mujer que consultó por infantilismo sexual y amenorrea primaria en presencia de cariotipo 46XX. Durante su evolución, cursó con hipertensión e hipokalemia que condujo a la sospecha diagnóstica de una hiperplasia adrenal congénita (HAC). El estudio genético reveló una mutación de cambio de sentido erróneo, homocigota, en el exón 8, c.1250T>C; p.Phe417Ser del gen de la CYP17A1. Se ha demostrado previamente que mutaciones en esta localización suprimen las actividades de 17α-hidroxilasa y 17,20-liasa, lo que explica el fenotípico clínico observado. Reportamos por primera vez en el mundo la mutación de cambio de sentido erróneo, c.1250T>C; p.Phe417Ser, en el gen CYP17A1, relacionada con la HAC. Discusión y conclusión: los análisis genéticos en todos los pacientes con HAC son necesarios para definir la frecuencia de esta y otras mutaciones en la población colombiana y relacionar el fenotipo de la enfermedad con su genotipo. Mención de responsabilidad : Carlos E. Builes-Montaño, Myriam V. Rueda-Galvis, María C. Fragozo-Ramos, Valentina Agredo-Delgado, Julián Zea-Lopera, Carlos M. Muñetón-Peña DOI (Digital Object Identifier) : 10.53853/encr.9.2.750 Derechos de uso : CC BY-NC-ND En línea : https://revistaendocrino.org/index.php/rcedm/article/view/750 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6060

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001904	AC-2022-068	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

AC-2022-068 Adobe Acrobat PDF

Insulinoma-related endogenous hypoglycaemia with a negative fasting test: a case report and literature review / Carolina Prieto Saldarriaga ; Carlos Esteban Builes Montaño ; Clara María Arango Toro  

Público ISBD Título : Insulinoma-related endogenous hypoglycaemia with a negative fasting test: a case report and literature review Tipo de documento : documento electrónico Autores : Carolina Prieto Saldarriaga, ; Carlos Esteban Builes Montaño, ; Clara María Arango Toro, Fecha de publicación : 2022 Títulos uniformes : European Journal of Case Reports in Internal Medicine Idioma : Inglés (eng) Palabras clave : Insulinoma  hyperinsulinaemia  fasting Resumen : We present the case of a patient with a history of symptomatic hypoglycaemic episodes and a negative 72-hour fasting test with histological confirmation of insulinoma. A literature review of hyperinsulinaemic hypoglycaemia with a negative fasting test was performed. Mención de responsabilidad : Carolina Prieto-Saldarriaga, Carlos Esteban Builes-Montaño, Clara María Arango-Toro, Cindy Manotas-Echeverry, Juan Camilo Pérez-Cadavid, José C Álvarez-Payares, Luis Antonio Rodríguez-Arrieta Referencia : Eur J Case Rep Intern Med. 2022 Sep 9;9(9):003484. DOI (Digital Object Identifier) : 10.12890/2022_003484 PMID : 36299851 En línea : https://www.ejcrim.com/index.php/EJCRIM/article/view/3484 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6105 Insulinoma-related endogenous hypoglycaemia with a negative fasting test: a case report and literature review [documento electrónico] / Carolina Prieto Saldarriaga, ; Carlos Esteban Builes Montaño, ; Clara María Arango Toro,  . - 2022. Obra : European Journal of Case Reports in Internal Medicine Idioma : Inglés (eng) Palabras clave : Insulinoma  hyperinsulinaemia  fasting Resumen : We present the case of a patient with a history of symptomatic hypoglycaemic episodes and a negative 72-hour fasting test with histological confirmation of insulinoma. A literature review of hyperinsulinaemic hypoglycaemia with a negative fasting test was performed. Mención de responsabilidad : Carolina Prieto-Saldarriaga, Carlos Esteban Builes-Montaño, Clara María Arango-Toro, Cindy Manotas-Echeverry, Juan Camilo Pérez-Cadavid, José C Álvarez-Payares, Luis Antonio Rodríguez-Arrieta Referencia : Eur J Case Rep Intern Med. 2022 Sep 9;9(9):003484. DOI (Digital Object Identifier) : 10.12890/2022_003484 PMID : 36299851 En línea : https://www.ejcrim.com/index.php/EJCRIM/article/view/3484 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6105

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001953	AC-2022-114	Archivo digital	Producción Científica	Artículos científicos	Disponible

Late systemic lupus erythematosus-associated insulin resistance syndrome: a rare cause of de novo diabetes mellitus / Carlos Esteban Builes Montaño ; Carolina Prieto Saldarriaga ; Clara María Arango Toro ; Juan Guillermo Gamboa Arroyave    

Público ISBD Título : Late systemic lupus erythematosus-associated insulin resistance syndrome: a rare cause of de novo diabetes mellitus Tipo de documento : documento electrónico Autores : Carlos Esteban Builes Montaño, ; Carolina Prieto Saldarriaga, ; Clara María Arango Toro, ; Juan Guillermo Gamboa Arroyave, Fecha de publicación : 2022 Títulos uniformes : Case Reports in Medicine Idioma : Inglés (eng) Resumen : The association of type B insulin resistance syndrome (TBIRS) due to autoimmune diseases such as systemic lupus erythematosus (SLE) is uncommon. This is partly due to the lack of established criteria for the diagnosis of this resistance. However, some clinical aspects may suggest that the diagnosis does not necessarily have to be positive insulin receptor antibodies as such patients could respond to immunosuppressive treatment. Methods. We describe a case and have performed a literature review on PubMed/MEDLINE, EMBASE, and Google Scholar bibliographic databases to identify all case reports. All available studies from January 1975 through December 2020 were included. Data collected were tabulated, and outcomes were analyzed cumulatively. Results. Thirty-one cases of TBIRS associated with SLE have been described. These patients presented with catabolic symptoms and hyperglycemia in most cases, with an average time from the onset of symptoms of four months. In addition to that clinical characteristics related to SLE were variable, along with certain common characteristics such as acanthosis in 60% of patients. Almost all the patients had antibodies against insulin receptors. The insulin doses required by the patients ranged from 450 to 25,000 U daily. Remission was achieved in 80% of the patients with a two-year follow-up. Most patients associated with late-onset SLE, like our patient, achieved metabolic control after immunosuppressive treatment. Conclusion. High insulin resistance in patients with de novo diabetes mellitus (DM) without obesity should be considered as a possible clinical manifestation of an autoimmune disease such as SLE, with a good metabolic response to the immunosuppressive management established. Mención de responsabilidad : José C Alvarez-Payares, Daniel Ribero, Luis Rodríguez, Carlos E Builes, Carolina Prieto, Clara Arango, Juan G Gamboa, Cristian Alvarez-Payares Referencia : Case Rep Med. 2022 Oct 14;2022:4655804. DOI (Digital Object Identifier) : 10.1155/2022/4655804 PMID : 36275943 Derechos de uso : CC BY En línea : https://www.hindawi.com/journals/crim/2022/4655804/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6075 Late systemic lupus erythematosus-associated insulin resistance syndrome: a rare cause of de novo diabetes mellitus [documento electrónico] / Carlos Esteban Builes Montaño, ; Carolina Prieto Saldarriaga, ; Clara María Arango Toro, ; Juan Guillermo Gamboa Arroyave,  . - 2022. Obra : Case Reports in Medicine Idioma : Inglés (eng) Resumen : The association of type B insulin resistance syndrome (TBIRS) due to autoimmune diseases such as systemic lupus erythematosus (SLE) is uncommon. This is partly due to the lack of established criteria for the diagnosis of this resistance. However, some clinical aspects may suggest that the diagnosis does not necessarily have to be positive insulin receptor antibodies as such patients could respond to immunosuppressive treatment. Methods. We describe a case and have performed a literature review on PubMed/MEDLINE, EMBASE, and Google Scholar bibliographic databases to identify all case reports. All available studies from January 1975 through December 2020 were included. Data collected were tabulated, and outcomes were analyzed cumulatively. Results. Thirty-one cases of TBIRS associated with SLE have been described. These patients presented with catabolic symptoms and hyperglycemia in most cases, with an average time from the onset of symptoms of four months. In addition to that clinical characteristics related to SLE were variable, along with certain common characteristics such as acanthosis in 60% of patients. Almost all the patients had antibodies against insulin receptors. The insulin doses required by the patients ranged from 450 to 25,000 U daily. Remission was achieved in 80% of the patients with a two-year follow-up. Most patients associated with late-onset SLE, like our patient, achieved metabolic control after immunosuppressive treatment. Conclusion. High insulin resistance in patients with de novo diabetes mellitus (DM) without obesity should be considered as a possible clinical manifestation of an autoimmune disease such as SLE, with a good metabolic response to the immunosuppressive management established. Mención de responsabilidad : José C Alvarez-Payares, Daniel Ribero, Luis Rodríguez, Carlos E Builes, Carolina Prieto, Clara Arango, Juan G Gamboa, Cristian Alvarez-Payares Referencia : Case Rep Med. 2022 Oct 14;2022:4655804. DOI (Digital Object Identifier) : 10.1155/2022/4655804 PMID : 36275943 Derechos de uso : CC BY En línea : https://www.hindawi.com/journals/crim/2022/4655804/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6075

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001919	AC-2022-083	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

AC-2022-083 Adobe Acrobat PDF

Main glucose hepatic fluxes in healthy subjects predicted from a phenomenological-based model / Carlos Esteban Builes Montaño    

Permalink

Short-term effectiveness and reduction in insulin requirements in patients with type 2 diabetes treated With IdegLira in a real-world setting / Carlos Esteban Builes Montaño    

Permalink

STUDIA: An application to support carbohydrate counting by simulating glucose dynamics / Carlos Esteban Builes Montaño    

Permalink

Tiroiditis subaguda y tirotoxicosis posterior a vacuna contra SARS-CoV-2: reporte de 2 casos / Isabel Cristina Ramírez Sánchez ; Carlos Esteban Builes Montaño ; Alejandro Vélez Hoyos    

Permalink

Diabetes mellitus y COVID-19: fisiopatología y propuesta de tratamiento para el control glucémico en el tiempo de la pandemia / Carlos Esteban Builes Montaño ; Clara María Arango Toro  

Permalink

Diabetes mellitus y COVID-19: fisiopatología y propuesta de tratamiento para el control glucémico en el tiempo de la pandemia / Carlos Esteban Builes Montaño ; Clara María Arango Toro    

Permalink

Enfermedad hepática grasa no alcohólica en personas no obesas: revisión narrativa de la literatura / Juan Carlos Restrepo Gutiérrez ; Carlos Esteban Builes Montaño    

Permalink

Identifiability of control-oriented glucose-insulin linear models: review and analysis / Carlos Esteban Builes Montaño    

Permalink

Patrones de práctica clínica en la enfermedad de Graves en Colombia / Carlos Esteban Builes Montaño ; Jorge Hernando Donado Gómez    

Permalink

A phenomenological-based semi-physical model of the kidneys and its role in glucose metabolism / Carlos Esteban Builes Montaño  

Permalink

---

1 2 3 (1 - 15 / 35) Por página: 25 50 100 200